CAS · 439239-90-4
Product Overview
LasMiditan is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance | Yellow to off-white powder |
|---|---|
| Purity | 99% min |
| Water content | 1% max |
| Residue on ignition | 0.1% max |
| Related substances | Single max unknown impurity 0.5% max |
Applications
Lasmiditan is a selective serotonin 5-HT1F receptor agonist used in pharmaceutical research and clinical applications for the treatment of acute migraine attacks. Unlike traditional triptans, Lasmiditan does not cause vasoconstriction, making it suitable for patients with cardiovascular risk factors. It is primarily applied in oral formulations for rapid relief of migraine symptoms, including headache, nausea, and sensitivity to light or sound. In research, Lasmiditan is employed to study migraine pathophysiology, receptor-specific signaling pathways, and the development of novel therapeutic agents targeting serotonergic mechanisms.
Benefits
The benefits of Lasmiditan include its high selectivity for the 5-HT1F receptor, which reduces the risk of cardiovascular side effects associated with non-selective serotonergic drugs. Its rapid onset of action provides effective relief from migraine symptoms, improving patient quality of life. The compound's oral bioavailability and predictable pharmacokinetics make it convenient for clinical use. Additionally, Lasmiditan's receptor specificity allows researchers to explore targeted mechanisms in migraine therapy, supporting the development of safer and more effective treatment options for diverse patient populations.
Conclusion
Lasmiditan is a selective 5-HT1F receptor agonist used for acute migraine treatment and pharmacological research. Its receptor specificity, rapid efficacy, and favorable safety profile make it an important therapeutic agent and research tool. These properties support its role in improving migraine management and advancing understanding of serotonergic signaling in neurological disorders.
Previous
Next